News
TXMD
1.830
+2.23%
0.040
UPDATE 2-Australia's Mayne Pharma sues Indian drugmaker Sun Pharma over patent infringement
Australia's Mayne Pharma sues Indian drugmaker Sun Pharma over patent infringement. Mayne accuses rival of violating all 20 Orange Book-listed patents linked to IMVEXXY. The vaginal insert is used to reduce pain during sexual intercourse after menopause. Sun Pharma is seeking approval to market a generic version of the product in the U.S.
Reuters · 2d ago
Weekly Report: what happened at TXMD last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at TXMD last week (0708-0712)?
Weekly Report · 07/15 09:25
Weekly Report: what happened at TXMD last week (0701-0705)?
Weekly Report · 07/08 09:25
Weekly Report: what happened at TXMD last week (0624-0628)?
Weekly Report · 07/01 09:25
Weekly Report: what happened at TXMD last week (0617-0621)?
Weekly Report · 06/24 09:27
Weekly Report: what happened at TXMD last week (0610-0614)?
Weekly Report · 06/17 09:25
Weekly Report: what happened at TXMD last week (0603-0607)?
Weekly Report · 06/10 09:25
Weekly Report: what happened at TXMD last week (0527-0531)?
Weekly Report · 06/03 09:26
Nektar, Verastem among healthcare additions in Russell Microcap; Assertio, Sangamo removed
Nektar, Verastem among healthcare additions in Russell Microcap; Assertio, Sangamo removed from the index. 213 companies will be added and 198 deleted from the annual 2024 Russell index reconstitution. Inovio Pharmaceuticals, Nektar, Ocugen among notable additions.
Seeking Alpha · 05/30 20:55
Weekly Report: what happened at TXMD last week (0520-0524)?
Weekly Report · 05/27 09:27
Weekly Report: what happened at TXMD last week (0513-0517)?
Weekly Report · 05/20 09:26
Weekly Report: what happened at TXMD last week (0506-0510)?
Weekly Report · 05/13 09:27
Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Press release · 05/11 08:33
TXMD Stock Earnings: TherapeuticsMD Reported Results for Q1 2024
TherapeuticsMD just reported results for the first quarter of 2024. The company reported earnings per share of -7 cents and revenue of $313,000. Therapeutics MD is a biopharmaceutical company that develops drugs to treat cancer and other conditions in the body.
Investorplace · 05/11 00:53
TherapeuticsMD Releases Preliminary Q1 2024 Financials
TipRanks · 05/10 20:34
Therapeutics MD GAAP EPS of -$0.07
Seeking Alpha · 05/10 20:17
TherapeuticsMD Q1 EPS $(0.07) Up From $(0.24) YoY
Benzinga · 05/10 20:07
THERAPEUTICSMD INC - CONTINUES TO EVALUATE A VARIETY OF STRATEGIC ALTERNATIVES
Reuters · 05/10 20:05
*TherapeuticsMD 1Q Cont Ops Loss/Shr 7c >TXMD
Dow Jones · 05/10 20:05
More
Webull provides a variety of real-time TXMD stock news. You can receive the latest news about Therapeuticsmd Inc through multiple platforms. This information may help you make smarter investment decisions.
About TXMD
TherapeuticsMD, Inc. is a pharmaceutical royalty company, which primarily collects royalties from its licensees. It receives royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. It granted a license to commercialize IMVEXXY, BIJUVA, and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands and assigned its exclusive license to commercialize ANNOVERA to Mayne Pharma. IMVEXXY (estradiol vaginal inserts) pharmaceutical product is for the treatment of moderate-to-severe dyspareunia. BIJUVA pharmaceutical product is a Food and Drug Administration (FDA)-approved bioidentical hormone therapy combination of estradiol and progesterone in a single, oral capsule for the treatment of moderate-to-severe vasomotor symptoms due to menopause in women with a uterus. ANNOVERA pharmaceutical product is a one-year ring-shaped contraceptive vaginal system (CVS).